Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Celldex Therapeutics Stories

2013-04-19 12:28:18

CHICAGO, April 19, 2013 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIG, LULU, CF, CLDX, and ALK. (Photo: http://photos.prnewswire.com/prnh/20120712/CG39046) To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/41820131 (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: Transocean...

2013-03-07 08:29:48

BETHESDA, Md., March 7, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that it expects to complete enrollment in its 312-patient Phase III clinical trial for Glioblastoma multiforme (GBM) brain cancer within a period that is faster or more efficient than relevant comparison trials with immune therapies for the same brain cancer. The...

2008-11-12 12:00:31

Celldex Therapeutics, an integrated biopharmaceutical company, has signed an exclusive patent and know-how license agreement with the University of Southampton, UK, to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers. In preclinical models, antibodies to CD27 have been shown to mediate anti-tumor effects alone, and may be particularly effective in combination with other immunotherapies. Financial terms of the transaction were not...

2008-11-04 03:00:05

Celldex Therapeutics, an integrated biopharmaceutical company, has announced initial results from multi-center Phase I clinical trials of its cancer vaccine candidate, CDX-1307, combined with GM-CSF. These data provide the basis for the ongoing assessment of CDX-1307 combined with more potent adjuvants with data expected in the first half of 2009. The Phase I studies are open-label, dose-escalating clinical trials in patients with incurable breast, bladder, pancreatic, or colorectal cancer,...

2008-10-03 09:00:38

Celldex Therapeutics, an integrated biopharmaceutical company, has received a milestone payment of $10 million from an affiliate of Paul Capital Healthcare. The payment was triggered by the market launch of Rotarix in the US. Rotarix is marketed worldwide by GlaxoSmithKline. John Leone, a partner at Paul Capital Healthcare, said: "In purchasing a portion of Celldex's Rotarix royalty stream, Paul Capital Healthcare has helped Celldex to monetize a previously under-appreciated asset. The...